{
    "id": 25680,
    "fullName": "AURKA positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "AURKA positive indicates the presence of the AURKA gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 6790,
        "geneSymbol": "AURKA",
        "terms": [
            "AURKA",
            "AIK",
            "ARK1",
            "AURA",
            "BTAK",
            "PPP1R47",
            "STK15",
            "STK6",
            "STK7"
        ]
    },
    "variant": "positive",
    "createDate": "10/27/2016",
    "updateDate": "07/08/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 10664,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AKI603 inhibited Aurora kinase A activity and proliferation in acute myeloid leukemia cell lines in culture (PMID: 27824120).",
            "molecularProfile": {
                "id": 26698,
                "profileName": "AURKA positive"
            },
            "therapy": {
                "id": 4073,
                "therapyName": "AKI603",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8727,
                    "pubMedId": 27824120,
                    "title": "Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27824120"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10665,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AKI603 inhibited Aurora kinase A activity and proliferation in chronic myeloid leukemia cell lines in culture (PMID: 27824120).",
            "molecularProfile": {
                "id": 26698,
                "profileName": "AURKA positive"
            },
            "therapy": {
                "id": 4073,
                "therapyName": "AKI603",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8727,
                    "pubMedId": 27824120,
                    "title": "Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27824120"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10667,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AKI603 inhibited Aurora kinase A activity and proliferation in acute lymphocytic leukemia cell lines in culture (PMID: 27824120).",
            "molecularProfile": {
                "id": 26698,
                "profileName": "AURKA positive"
            },
            "therapy": {
                "id": 4073,
                "therapyName": "AKI603",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8727,
                    "pubMedId": 27824120,
                    "title": "Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27824120"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9036,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Alisertib (MLN8237) in culture did not result in decreased expression of MYCN and led to minimal effects on cell viability in a neuroendocrine prostate cancer cell line positive for AKT1, AURKA, and MYCN (PMID: 27050099).",
            "molecularProfile": {
                "id": 26699,
                "profileName": "AKT1 pos AURKA pos MYCN pos"
            },
            "therapy": {
                "id": 626,
                "therapyName": "Alisertib",
                "synonyms": null
            },
            "indication": {
                "id": 2992,
                "name": "prostate neuroendocrine neoplasm",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6885,
                    "pubMedId": 27050099,
                    "title": "N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27050099"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9035,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a neuroendocrine prostate cancer cell line, positive for AKT1, AURKA, and MYCN, demonstrated decreased MYCN expression and reduced cell viability in culture, and decreased tumor volume in xenograft models when treated with CD532 (PMID: 27050099).",
            "molecularProfile": {
                "id": 26699,
                "profileName": "AKT1 pos AURKA pos MYCN pos"
            },
            "therapy": {
                "id": 1628,
                "therapyName": "CD532",
                "synonyms": null
            },
            "indication": {
                "id": 2992,
                "name": "prostate neuroendocrine neoplasm",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6885,
                    "pubMedId": 27050099,
                    "title": "N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27050099"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10668,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AKI603 inhibited Aurora kinase A activity and proliferation of chronic myeloid leukemia cells over expressing ABL1 T315I in the context of BCR-ABL1 in culture, resulted in tumor inhibition in cell line xenograft models (PMID: 27824120).",
            "molecularProfile": {
                "id": 27720,
                "profileName": "BCR - ABL1 ABL1 T315I AURKA pos"
            },
            "therapy": {
                "id": 4073,
                "therapyName": "AKI603",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8727,
                    "pubMedId": 27824120,
                    "title": "Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27824120"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10669,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AKI603 and Gleevec (imatinib) synergistically inhibited proliferation and colony formation in chronic myeloid leukemia cells over expressing ABL1 T315I in the context of BCR-ABL1 in culture (PMID: 27824120).",
            "molecularProfile": {
                "id": 27720,
                "profileName": "BCR - ABL1 ABL1 T315I AURKA pos"
            },
            "therapy": {
                "id": 5572,
                "therapyName": "AKI603 + Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8727,
                    "pubMedId": 27824120,
                    "title": "Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27824120"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10687,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TY-011 inhibited activities of Aurora kinase A and Aurora kinase B, resulting in growth inhibition in culture and decrease tumor size and angiogenesis in cell line xenograft models of gastric cancer (PMID: 27887633).",
            "molecularProfile": {
                "id": 27730,
                "profileName": "AURKA pos AURKB pos"
            },
            "therapy": {
                "id": 5586,
                "therapyName": "TY-011",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8743,
                    "pubMedId": 27887633,
                    "title": "Antitumor activity of TY-011 against gastric cancer by inhibiting Aurora A, Aurora B and VEGFR2 kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27887633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11536,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, hepatocellular carcinoma cell lines positive for AURKA and AURKB were sensitive to SNS-314 in culture, demonstrating reduced cell proliferation, induced apoptotic activity, and suppression of YAP activity, a result of AURKA and AURKB inhibition, which led to P21 activity (PMID: 28427193).",
            "molecularProfile": {
                "id": 27730,
                "profileName": "AURKA pos AURKB pos"
            },
            "therapy": {
                "id": 918,
                "therapyName": "SNS-314",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9606,
                    "pubMedId": 28427193,
                    "title": "Targeting high Aurora kinases expression as an innovative therapy for hepatocellular carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28427193"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26698,
            "profileName": "AURKA positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26699,
            "profileName": "AKT1 pos AURKA pos MYCN pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27720,
            "profileName": "BCR - ABL1 ABL1 T315I AURKA pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27730,
            "profileName": "AURKA pos AURKB pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}